Literature DB >> 14610215

Infection with multiple human immunodeficiency virus type 1 variants is associated with faster disease progression.

Manish Sagar1, Ludo Lavreys, Jared M Baeten, Barbra A Richardson, Kishorchandra Mandaliya, Bhavna H Chohan, Joan K Kreiss, Julie Overbaugh.   

Abstract

Human immunodeficiency virus type 1 (HIV-1)-infected individuals develop a genetically diverse virus population over time, but often only a limited number of viral variants are transmitted from a chronic carrier to a newly infected person. Interestingly, many women but few men are infected by multiple HIV-1 variants from a single partner. To determine whether the complexity of the infecting virus population influences clinical outcome, we examined viral diversity in the HIV-1 envelope sequences present at primary infection in 156 women from Kenya for whom we had follow-up data on viral RNA levels and CD4 T-cell counts. Eighty-nine women had multiple viral genotypes, while 67 women had a single genotype at primary infection. Women who acquired multiple viral genotypes had a significantly higher viral load (median, 4.84 versus 4.64 log(10) copies/ml, P = 0.04) and a significantly lower CD4(+)-T-cell count (median, 416 versus 617 cells/mm(3), P = 0.01) 4 to 24 months after infection compared to women who were infected with a single viral genotype. These studies suggest that early HIV-1 genetic diversity is linked to faster disease progression.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14610215      PMCID: PMC262567          DOI: 10.1128/jvi.77.23.12921-12926.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  39 in total

1.  Emerging cytopathic and antigenic simian immunodeficiency virus variants influence AIDS progression.

Authors:  J T Kimata; L Kuller; D B Anderson; P Dailey; J Overbaugh
Journal:  Nat Med       Date:  1999-05       Impact factor: 53.440

2.  Patterns of HIV-1 evolution in individuals with differing rates of CD4 T cell decline.

Authors:  R B Markham; W C Wang; A E Weisstein; Z Wang; A Munoz; A Templeton; J Margolick; D Vlahov; T Quinn; H Farzadegan; X F Yu
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-13       Impact factor: 11.205

3.  Exponential fitness gains of RNA virus populations are limited by bottleneck effects.

Authors:  I S Novella; J Quer; E Domingo; J J Holland
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

4.  Gender differences in HIV-1 diversity at time of infection.

Authors:  E M Long; H L Martin; J K Kreiss; S M Rainwater; L Lavreys; D J Jackson; J Rakwar; K Mandaliya; J Overbaugh
Journal:  Nat Med       Date:  2000-01       Impact factor: 53.440

5.  Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection.

Authors:  R Shankarappa; J B Margolick; S J Gange; A G Rodrigo; D Upchurch; H Farzadegan; P Gupta; C R Rinaldo; G H Learn; X He; X L Huang; J I Mullins
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

6.  Correlation between HIV sequence evolution, specific immune response and clinical outcome in vertically infected infants.

Authors:  E Halapi; T Leitner; M Jansson; G Scarlatti; P Orlandi; A Plebani; L Romiti; J Albert; H Wigzell; P Rossi
Journal:  AIDS       Date:  1997-11-15       Impact factor: 4.177

7.  Drastic fitness loss in human immunodeficiency virus type 1 upon serial bottleneck events.

Authors:  E Yuste; S Sánchez-Palomino; C Casado; E Domingo; C López-Galíndez
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

8.  Changes in the extracellular envelope glycoprotein of variants that evolve during the course of simian immunodeficiency virus SIVMne infection affect neutralizing antibody recognition, syncytium formation, and macrophage tropism but not replication, cytopathicity, or CCR-5 coreceptor recognition.

Authors:  L M Rudensey; J T Kimata; E M Long; B Chackerian; J Overbaugh
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

9.  Hormonal contraception, sexually transmitted diseases, and risk of heterosexual transmission of human immunodeficiency virus type 1.

Authors:  H L Martin; P M Nyange; B A Richardson; L Lavreys; K Mandaliya; D J Jackson; J O Ndinya-Achola; J Kreiss
Journal:  J Infect Dis       Date:  1998-10       Impact factor: 5.226

10.  Patterns of viral dynamics during primary human immunodeficiency virus type 1 infection. The Sydney Primary HIV Infection Study Group.

Authors:  G R Kaufmann; P Cunningham; A D Kelleher; J Zaunders; A Carr; J Vizzard; M Law; D A Cooper
Journal:  J Infect Dis       Date:  1998-12       Impact factor: 5.226

View more
  67 in total

1.  Short communication decreased incidence of dual infections in South african subtype C-infected women compared to a cohort ten years earlier.

Authors:  Zenda Woodman; Koleka Mlisana; Florette Treurnicht; Melissa-Rose Abrahams; Ruwayida Thebus; Salim Abdool Karim; Carolyn Williamson
Journal:  AIDS Res Hum Retroviruses       Date:  2011-02-09       Impact factor: 2.205

2.  SPMM: estimating infection duration of multivariant HIV-1 infections.

Authors:  Tanzy M T Love; Sung Yong Park; Elena E Giorgi; Wendy J Mack; Alan S Perelson; Ha Youn Lee
Journal:  Bioinformatics       Date:  2015-12-31       Impact factor: 6.937

3.  Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity.

Authors:  Manish Sagar; Xueling Wu; Sandra Lee; Julie Overbaugh
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

4.  Mucosal simian immunodeficiency virus transmission in African green monkeys: susceptibility to infection is proportional to target cell availability at mucosal sites.

Authors:  Ivona Pandrea; Nicholas F Parrish; Kevin Raehtz; Thaidra Gaufin; Hannah J Barbian; Dongzhu Ma; Jan Kristoff; Rajeev Gautam; Fang Zhong; George S Haret-Richter; Anita Trichel; George M Shaw; Beatrice H Hahn; Cristian Apetrei
Journal:  J Virol       Date:  2012-02-08       Impact factor: 5.103

5.  Association between latent proviral characteristics and immune activation in antiretrovirus-treated human immunodeficiency virus type 1-infected adults.

Authors:  Emily C Liang; Lindsay Sceats; Nicholas L Bayless; Dara M Strauss-Albee; Jessica Kubo; Philip M Grant; David Furman; Manisha Desai; David A Katzenstein; Mark M Davis; Andrew R Zolopa; Catherine A Blish
Journal:  J Virol       Date:  2014-05-21       Impact factor: 5.103

6.  Short Communication: A Recombinant Variant with Increased Envelope Entry Efficiency Emerged During Early Infection of an HIV-1 Subtype C Dual Infected Rapid Progressor.

Authors:  Kerry Gordon; Shatha Omar; Andile Nofemela; Gama Bandawe; Carolyn Williamson; Zenda Woodman
Journal:  AIDS Res Hum Retroviruses       Date:  2015-05-20       Impact factor: 2.205

7.  Homogenous HIV-1 subtype B quasispecies in Brazilian men and women recently infected via heterosexual transmission.

Authors:  Nancy Lima Gouveia; Michelle Camargo; Marcos Montani Caseiro; Luiz Mario Ramos Janini; Maria Cecilia Araripe Sucupira; Ricardo Sobhie Diaz
Journal:  Virus Genes       Date:  2014-02-14       Impact factor: 2.332

8.  Antigenic stimulation specifically reactivates the replication of archived simian immunodeficiency virus genomes in chronically infected macaques.

Authors:  Céline Renoux; Simon Wain-Hobson; Bruno Hurtrel; Rémi Cheynier
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

9.  Hormonal contraception and HIV disease progression: a multicountry cohort analysis of the MTCT-Plus Initiative.

Authors:  Elizabeth M Stringer; Mark Giganti; Rosalind J Carter; Wafaa El-Sadr; Elaine J Abrams; Jeffrey Sa Stringer
Journal:  AIDS       Date:  2009-11       Impact factor: 4.177

10.  HIV-1 evolution in gag and env is highly correlated but exhibits different relationships with viral load and the immune response.

Authors:  Anne Piantadosi; Bhavna Chohan; Dana Panteleeff; Jared M Baeten; Kishorchandra Mandaliya; Jeckoniah O Ndinya-Achola; Julie Overbaugh
Journal:  AIDS       Date:  2009-03-13       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.